SCHEMBL21351963

SCHEMBL21351963

CCc1cc(Br)c(C(=O)O)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA3 P07451 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA13 Q8N1Q1 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
CISD1 Q9NZ45 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984008 0.85 TSHR (0.42) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL29382963 0.85 CA12 (0.44) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL19873252 0.84 HSD17B10 (0.56) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL4640738 0.84 ALDH1A1 (0.47) TSHRHSD17B10ALDH1A1TP53CA12
SCHEMBL6858908 0.82 CA12 (0.50) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL3366164 0.80 LCK (0.50) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL8189899 0.79 KDM4E (0.49) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL8678983 0.78 CA1 (0.52) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL21352065 0.78 HSD17B10 (0.50) TSHRHSD17B10LCKFYNALDH1A1
SCHEMBL21352106 0.78 HSD17B10 (0.50) TSHRHSD17B10LCKFYNCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 TSHR 4115/4885HSD17B10 3483/4885LCK 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.